Iovance Biotherapeutics Valuation
| IOVA Stock | USD 2.49 0.29 13.18% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Iovance Biotherapeutics retains a regular Real Value of $4.08 per share. The prevalent price of the firm is $2.49. Our model calculates the value of Iovance Biotherapeutics from evaluating the firm fundamentals such as Return On Asset of -0.27, current valuation of 548.06 M, and Return On Equity of -0.53 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Iovance Biotherapeutics' valuation include:
Price Book 1.1397 | Enterprise Value | Enterprise Value Ebitda (8.68) | Price Sales 3.311 | Enterprise Value Revenue 2.2692 |
Undervalued
Today
Please note that Iovance Biotherapeutics' price fluctuation is very risky at this time. Calculation of the real value of Iovance Biotherapeutics is based on 3 months time horizon. Increasing Iovance Biotherapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Iovance Biotherapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Iovance Stock. However, Iovance Biotherapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.49 | Real 4.08 | Target 9.1 | Hype 2.47 | Naive 2.65 |
The real value of Iovance Stock, also known as its intrinsic value, is the underlying worth of Iovance Biotherapeutics Company, which is reflected in its stock price. It is based on Iovance Biotherapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Iovance Biotherapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Iovance Biotherapeutics helps investors to forecast how Iovance stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Iovance Biotherapeutics more accurately as focusing exclusively on Iovance Biotherapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Iovance Biotherapeutics' intrinsic value based on its ongoing forecasts of Iovance Biotherapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Iovance Biotherapeutics' closest peers. If more than one evaluation category is relevant for Iovance Biotherapeutics we suggest using both methods to arrive at a better estimate.
Iovance Biotherapeutics Cash |
|
Iovance Valuation Trend
Comparing Iovance Biotherapeutics' enterprise value against its market capitalization is a good way to estimate the value of Iovance Biotherapeutics uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Iovance Biotherapeutics Total Value Analysis
Iovance Biotherapeutics is currently anticipated to have valuation of 548.06 M with market capitalization of 799.7 M, debt of 58.26 M, and cash on hands of 424.46 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Iovance Biotherapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
548.06 M | 799.7 M | 58.26 M | 424.46 M |
Iovance Biotherapeutics Investor Information
About 69.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 1.14. Some equities with similar Price to Book (P/B) outperform the market in the long run. Iovance Biotherapeutics recorded a loss per share of 1.2. The entity had not issued any dividends in recent years. The firm had 1:100 split on the 26th of September 2013. Based on the key indicators related to Iovance Biotherapeutics' liquidity, profitability, solvency, and operating efficiency, Iovance Biotherapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in October.Iovance Biotherapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Iovance Biotherapeutics has an asset utilization ratio of 18.02 percent. This suggests that the Company is making $0.18 for each dollar of assets. An increasing asset utilization means that Iovance Biotherapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Iovance Biotherapeutics Ownership Allocation
Iovance Biotherapeutics has a total of 361.85 Million outstanding shares. Over half of Iovance Biotherapeutics' outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Iovance Biotherapeutics Profitability Analysis
The company reported the previous year's revenue of 164.07 M. Net Loss for the year was (372.18 M) with profit before overhead, payroll, taxes, and interest of 49.75 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Iovance Biotherapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Iovance Biotherapeutics and how it compares across the competition.
About Iovance Biotherapeutics Valuation
The stock valuation mechanism determines Iovance Biotherapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Iovance Biotherapeutics. We calculate exposure to Iovance Biotherapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Iovance Biotherapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 40.1 M | 42.1 M | |
| Pretax Profit Margin | (2.29) | (2.40) | |
| Operating Profit Margin | (2.41) | (2.53) | |
| Net Loss | (2.27) | (2.38) | |
| Gross Profit Margin | 0.24 | 0.26 |
Iovance Biotherapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 289.9 M |
Iovance Biotherapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Iovance Biotherapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Iovance we look at many different elements of the entity such as Iovance's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Iovance Biotherapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Iovance Biotherapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Iovance Biotherapeutics' worth.Complementary Tools for Iovance Stock analysis
When running Iovance Biotherapeutics' price analysis, check to measure Iovance Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iovance Biotherapeutics is operating at the current time. Most of Iovance Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Iovance Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iovance Biotherapeutics' price. Additionally, you may evaluate how the addition of Iovance Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |